AstraZeneca withdraws application for lung cancer drug in EU
AstraZeneca has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its ...
FDA alerting veterinarians after reports of health problems in dogs tied to arthritis drug
Channel 2 Action News has learned that the FDA is now alerting veterinarians about reports of health problems in dogs – ...
Novo Nordisk's Ozempic faces EU review for potential eye disease connection
The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes ...
EU Drug Regulator to Review Ozempic’s Possible Link to Eye Condition
The European Union’s drug regulator said it would review two studies that link Novo Nordisk’s blockbuster diabetes drug ...
AstraZeneca, Daiichi pull EU marketing application for lung cancer drug, Dato-DXd
AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) withdraw EU marketing application for lung cancer therapy Dato-DXd. Read more ...
European markets higher in shortened session ahead of Christmas; Novo Nordisk resumes recovery
Novo Nordisk resumed its rally on Tuesday, rising to the top of the Stoxx 600 during early deals and adding 5.7% by 11:05 a.m ...
Bio-Thera Solutions Partners With Tabuk Pharmaceuticals To Commercialize BAT2206, A Stelara® (Ustekinumab) Biosimilar In Saudi Arabia
BAT2206 is a proposed biosimilar to Jansen's Stelara®. Bio-Thera has filed for regulatory approval of BAT2206 with the China ...
AstraZeneca, Daiichi Sankyo Withdraw Authorization Application for Lung Cancer Treatment in EU
AstraZeneca said it and Daiichi Sankyo decided to voluntarily withdraw the marketing authorization application in the European Union for advanced lung-cancer treatment Dato-DXd. This decision followed ...
Zacks.com on MSN2h
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer
Bristol Myers Squibb BMY announced that the European Commission has approved the combination of its blockbuster ...
Cytokinetics announces EMA has validated MAA for aficamten
Cytokinetics (CYTK) announced that the European Medicines Agency, EMA, has validated the Marketing Authorization Application, MAA, for ...
Anavex receives EMA filing acceptance for treatment of Alzheimer’s disease
Life Sciences announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorization Application, ...